Literature DB >> 18080155

Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus.

Corinna S Bowser1, Swati Kumar, Louis Salciccioli, Andrei Kutlin, Jason Lazar, Imran Rahim, Amy Suss, Stephan Kohlhoff, Margaret R Hammerschlag, Hamid Jack Moallem.   

Abstract

Patients with systemic lupus erythematosus (SLE) have accelerated atherogenesis. A recent study suggested that Chlamydia pneumoniae infection might also be a contributing factor in the development of atherogenesis in patients with SLE. The objective of this study was to investigate the possible association of C. pneumoniae infection with markers of atherosclerosis in adolescents with SLE compared with age-matched healthy controls. History and exam focused on cardiovascular risk factors were obtained from 20 patients with SLE and 20 age- and sex-matched controls. Laboratory studies included serum lipid profile and high-sensitivity C-reactive protein (hsCRP). Detection of C. pneumoniae in peripheral blood mononuclear cells (PBMCs) and in nasopharyngeal swab specimens was performed. Carotid Intima-Media Thickness (CIMT) was determined by sonography in all subjects. C. pneumoniae DNA was not detected in PBMCs of any of the patients or controls. Nasopharyngeal cultures were also negative for C. pneumoniae in all patients. CIMT was slightly higher in the SLE group (0.48 +/- 0.049) compared with controls (0.454 +/- 0.041, p = 0.29). There was no significant difference between the two groups in body mass index, blood pressure, hsCRP, and serum cholesterol (total, LDL and HDL). Serum triglycerides were higher in the lupus group (p = 0.03). Children and adolescents with SLE might have accelerated atherosclerosis; however, we did not observe an association with C. pneumoniae infection in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080155     DOI: 10.1007/s00246-007-9131-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  33 in total

1.  Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study.

Authors:  A I del Sol; K G Moons; M Hollander; A Hofman; P J Koudstaal; D E Grobbee; M M Breteler; J C Witteman; M L Bots
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

2.  Comparison of a new quantitative ompA-based real-Time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays.

Authors:  Petra Apfalter; Wolfgang Barousch; Marion Nehr; Athanasios Makristathis; Birgit Willinger; Manfred Rotter; Alexander M Hirschl
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations.

Authors:  A Kol; P Libby
Journal:  Trends Cardiovasc Med       Date:  1998-07       Impact factor: 6.677

4.  Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus.

Authors:  M Gazarian; B M Feldman; L N Benson; D L Gilday; R M Laxer; E D Silverman
Journal:  J Pediatr       Date:  1998-01       Impact factor: 4.406

5.  Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols.

Authors:  Petra Apfalter; Ojan Assadian; Francesco Blasi; Jens Boman; Charlotte A Gaydos; Michael Kundi; Athanasios Makristathis; Marion Nehr; Manfred L Rotter; Alexander M Hirschl
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

6.  Distribution and cross-sectional age-related increases of carotid artery intima-media thickness in young adults: the Bogalusa Heart Study.

Authors:  James H Stein; Pamela S Douglas; Sathanur R Srinivasan; M Gene Bond; Rong Tang; Shengxu Li; Wei Chen; Gerald S Berenson
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

7.  Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus.

Authors:  Faith Selzer; Kim Sutton-Tyrrell; Shirley G Fitzgerald; Joan E Pratt; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Arthritis Rheum       Date:  2004-01

8.  Is there a role for Chlamydia pneumoniae infection in systemic lupus erythematosus and in the associated atherosclerotic cardiovascular disease?

Authors:  T Kitumnuaypong; L V Scalzi; S Nalbant; J M Von Feldt; H R Schumacher
Journal:  Clin Exp Rheumatol       Date:  2004 May-Jun       Impact factor: 4.473

Review 9.  Cardiovascular risk assessment in individual patients from carotid intimal-medial thickness measurements.

Authors:  Ward A Riley
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

10.  Framingham risk score is related to carotid artery intima-media thickness in both white and black young adults: the Bogalusa Heart Study.

Authors:  Lyn Kieltyka; Elaine M Urbina; Rong Tang; M Gene Bond; Sathanur R Srinivasan; Gerald S Berenson
Journal:  Atherosclerosis       Date:  2003-09       Impact factor: 5.162

View more
  3 in total

1.  Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Authors:  S P Ardoin; L E Schanberg; C Sandborg; E Yow; H X Barnhart; K l Mieszkalski; N T Ilowite; E von Scheven; A Eberhard; D M Levy; Y Kimura; E Silverman; S L Bowyer; L Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L K Jung; L Imundo; J B Soep; A M Reed
Journal:  Lupus       Date:  2010-10       Impact factor: 2.911

Review 2.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 3.  Cardiovascular risk in pediatric-onset rheumatological diseases.

Authors:  Julie Barsalou; Timothy J Bradley; Earl D Silverman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.